Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General business news KBR secures subcontract with BSIT to enhance U.S. Air Force human performance optimization In a major announcement that highlights the intersection of defense contracting and human performance optimization, KBR revealed its… byPallavi MadhirajuMarch 19, 2024